In the remaining PALB2 affected carriers with HR + HER2- breast cancer, higher 21-gene recurrence scores (similar to that of BRCA2 carriers) have been reported, suggesting that tumor biology and chemotherapy response is likely similar between these groups [6]. This evidence concerns the gene ERBB2 and breast carcinoma.